Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

NCT02708095 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02708095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02708095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2016
Completion date
November 9, 2017
Enrollment
314 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus